It has the potential to help modify individuals’ underlying food allergy by desensitizing the immune system to an allergen. Viaskin, a patch-based non-oral immunotherapy, is a potential new class of treatment that harnesses the immune properties of the skin. Published in the New England Journal of Medicine, results showed that more than one-third (37-percent) of Viaskin Peanut-treated participants in the EPITOPE trial, sponsored by DBV Technologies, a clinical-stage biopharmaceutical company, reached a cumulative reactive dose ≥3444 mg. “The EPITOPE trial shows that the Viaskin peanut patch may not only be an effective treatment option but importantly a simple and safe option in this very young age group.” “With feeding guidelines now recommending the introduction of peanut in the first year of life, we are diagnosing peanut allergy earlier and earlier,” said Kim. “We hope this will be available to patients in the not too distant future.” “These are very encouraging results and move us closer to a treatment option for this increasingly prevalent and serious allergic condition,” said Burks. Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine is also a contributing author to the paper. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, evaluating the safety profile of Viaskin, a novel form of EPIT, among peanut-allergic toddlers shows that after 12 months of treatment in children aged 1-3 years, the treatment was found to be statistically superior to placebo in desensitizing participants to peanuts, increasing the peanut dose triggering allergic symptoms. The EPITOPE trial, led by senior author A. Currently there are no FDA approved treatment options for peanut-allergic children under the age of 4 years, but further research into the safety, efficacy, and tolerability of epicutaneous immunotherapy (EPIT) could play a significant role in novel options for immunotherapy. Peanut allergy affects approximately two percent of children in the United States, Canada, and other westernized countries, with a rapidly rising prevalence over the past 20 years.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |